<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04243551</url>
  </required_header>
  <id_info>
    <org_study_id>IMGX003-NIAID-1821</org_study_id>
    <secondary_id>U44AI134590</secondary_id>
    <nct_id>NCT04243551</nct_id>
  </id_info>
  <brief_title>Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients</brief_title>
  <official_title>Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study of the Efficacy and Safety of Latiglutenase Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet While Undergoing Periodic Gluten Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunogenics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Immunogenics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2b, multicenter, prospective, randomized, double-blind, placebo-controlled,&#xD;
      crossover study in symptomatic celiac disease patients attempting a GFD for at least one year&#xD;
      prior to screening.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2b, multicenter, prospective, randomized, double-blind, placebo-controlled,&#xD;
      crossover study in symptomatic celiac disease patients attempting a GFD for at least one year&#xD;
      prior to screening. Seropositive patients (blood test confirmed at Visit 0) will be scheduled&#xD;
      for a Screening Visit (Visit 1) whereas seronegative patients will be discontinued from study&#xD;
      participation (screen failures). Patients who meet Visit 1 protocol enrollment criteria will&#xD;
      be enrolled and begin the first of two 6 week periods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A two-period crossover design will be used where the two possible treatment sequences will be assigned at random.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The PI, CRA and study biostatistician will be masked until database lock.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom Severity Reduction</measure>
    <time_frame>6 months</time_frame>
    <description>The primary efficacy endpoint of this study is mean percent reduction in symptom severity relative to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>A secondary efficacy endpoint includes a change from baseline to end of study treatment period in health-related quality of life as measured by PGI-I health survey relative to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>A secondary efficacy endpoint includes a change from baseline to end of study treatment period in health-related quality of life as measured by PGI-S health survey relative to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>A secondary efficacy endpoint includes a change from baseline to end of study treatment period in health-related quality of life as measured by ICDSQ health survey relative to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>A secondary efficacy endpoint includes a change from baseline to end of study treatment period in health-related quality of life as measured by SF-12 health survey relative to placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>Latiglutenase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IMGX003</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latiglutenase</intervention_name>
    <description>Administered orally (daily)</description>
    <arm_group_label>Latiglutenase</arm_group_label>
    <other_name>IMGX003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally (daily)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy confirmed CD diagnosis&#xD;
&#xD;
          -  Seropositive&#xD;
&#xD;
          -  Gluten free diet (12 months minimum)&#xD;
&#xD;
          -  Experienced at least one self reported moderate or greater severity symptom during the&#xD;
             last 28 day period&#xD;
&#xD;
          -  Willing to take study treatment daily&#xD;
&#xD;
          -  Must sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Wheat allergy&#xD;
&#xD;
          -  History of peptic ulcer disease, esophagitis, IBS, IBD&#xD;
&#xD;
          -  Active colitis, dermatitis herpetiformis&#xD;
&#xD;
          -  Diagnosed with Type 1 Diabetes&#xD;
&#xD;
          -  Patients with known rapid gastric emptying (post-bariatric surgery, Billroth I or II&#xD;
             surgery)&#xD;
&#xD;
          -  Chronic infectious gastrointestinal illness or acute infectious gastrointestinal&#xD;
             illness within the 4 week period prior to screening&#xD;
&#xD;
          -  Known refractory celiac disease (RCD1 or RCD2)&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Murray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jack Syage, PhD</last_name>
    <phone>9496790900</phone>
    <email>jsyage@immunogenx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Ramos</last_name>
    <phone>9496790900</phone>
    <email>aramos@immunogenx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Celiac</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

